Short answer
MESA LABORATORIES INC /CO/ (MLAB) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $60M (up 1.0% year over year) with net income of $3M.
Q2 2026 key financials · XBRL
- Revenue
- $60M
- +1.0% YoY
- Net income
- $3M
- −40.3% YoY
- Operating margin
- 11.7%
- Gross margin
- 64.9%
- EPS (diluted)
- $0.49
- −42.4% YoY
Source: XBRL data from the MESA LABORATORIES INC /CO/ (MLAB) Q2 2026 10-Q on SEC EDGAR. USD.
MESA LABORATORIES INC /CO/ Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue up 1.0% YoY, driven by Calibration Solutions and Biopharmaceutical Development
- Gross margin increased 2.9 percentage points YoY, aided by lower contracted labor costs and favorable mix
- Best segments: Calibration Solutions and Biopharmaceutical Development; worst: Sterilization and Disinfection Control, with lower revenue
- Operating cash flow $14.7M, supporting $8.7M debt reduction
- Near-term headwinds: China weakness, tariffs, supply-chain challenges, cost pressures, and regulatory uncertainty
Risk Factors
- No material risk-factor changes identified; filing references the March 31, 2026 Form 10-K risk factors
- Tax-withholding share transfers: 10,125 shares purchased at $94.65 during June 2026
- Executive equity-sale arrangements: approximately 8,344 shares covered by Rule 10b5-1 plans
- Compliance exposure: executive trading arrangements adopted March 12, 2026 and expired June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MESA LABORATORIES INC /CO/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.